Nemaura Medical IncNASDAQ:NMRDNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3460
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.3460
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NMRD |
|---|---|---|
| 09:32 ET | 308 | 0.35 |
| 09:34 ET | 6328 | 0.35 |
| 09:36 ET | 5000 | 0.35 |
| 09:38 ET | 10000 | 0.35 |
| 09:41 ET | 2000 | 0.354951 |
| 09:52 ET | 245 | 0.350101 |
| 09:54 ET | 4000 | 0.3501 |
| 10:26 ET | 9504 | 0.3543 |
| 10:28 ET | 12090 | 0.361143 |
| 10:32 ET | 5000 | 0.360101 |
| 10:39 ET | 7230 | 0.3602 |
| 10:42 ET | 3729 | 0.3625 |
| 10:44 ET | 200 | 0.36 |
| 10:48 ET | 1351 | 0.36 |
| 10:51 ET | 12098 | 0.355 |
| 10:53 ET | 550 | 0.3621 |
| 11:00 ET | 1331 | 0.3551 |
| 11:02 ET | 17084 | 0.3401 |
| 11:04 ET | 2400 | 0.35 |
| 11:09 ET | 13325 | 0.3445 |
| 11:11 ET | 100 | 0.3445 |
| 11:15 ET | 900 | 0.347 |
| 11:18 ET | 1700 | 0.347 |
| 11:40 ET | 300 | 0.346 |
| 11:42 ET | 6000 | 0.3417 |
| 11:44 ET | 500 | 0.3454 |
| 11:47 ET | 200 | 0.3449 |
| 11:51 ET | 800 | 0.3449 |
| 11:54 ET | 100 | 0.3427 |
| 11:58 ET | 100 | 0.3449 |
| 12:00 ET | 100 | 0.345 |
| 12:03 ET | 100 | 0.3449 |
| 12:05 ET | 100 | 0.3428 |
| 12:16 ET | 2036 | 0.3412 |
| 12:18 ET | 600 | 0.345 |
| 12:21 ET | 2000 | 0.3414 |
| 12:23 ET | 4671 | 0.3415 |
| 12:25 ET | 3300 | 0.3425 |
| 12:38 ET | 1126 | 0.341701 |
| 12:52 ET | 100 | 0.34755 |
| 12:54 ET | 4936 | 0.341401 |
| 01:03 ET | 800 | 0.3418 |
| 01:17 ET | 1000 | 0.34585 |
| 01:32 ET | 6604 | 0.3423 |
| 01:35 ET | 270 | 0.3413 |
| 01:46 ET | 2360 | 0.3414 |
| 02:42 ET | 100 | 0.3415 |
| 03:00 ET | 100 | 0.3494 |
| 03:07 ET | 289 | 0.3494 |
| 03:16 ET | 2400 | 0.35 |
| 03:18 ET | 456 | 0.35 |
| 03:32 ET | 1000 | 0.3548 |
| 03:38 ET | 4457 | 0.348099 |
| 03:39 ET | 1116 | 0.3547 |
| 03:45 ET | 248 | 0.3545 |
| 03:59 ET | 1321 | 0.346 |
Sep 26, 2023
Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs., from 9:50AM ET on Tuesday Sep 26, 2023 by Dow Jones
9:50AM ET on Tuesday Sep 26, 2023 by Dow JonesNemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs., from 9:50AM ET on Tuesday Sep 26, 2023 by Dow Jones
9:50AM ET on Tuesday Sep 26, 2023 by Dow Jones
Sep 22, 2023
Sep 18, 2023
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference, from 9:15AM ET on Monday Sep 18, 2023 by Dow Jones
9:15AM ET on Monday Sep 18, 2023 by Dow JonesNemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference, from 9:15AM ET on Monday Sep 18, 2023 by Dow Jones
9:15AM ET on Monday Sep 18, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nemaura Medical Inc | 10.0M | -0.7x | --- |
Accustem Sciences Inc | 10.0M | -3.2x | --- |
bioAffinity Technologies Inc | 10.2M | -0.9x | --- |
Sigyn Therapeutics Inc | 11.9M | -2.9x | --- |
Sharps Technology Inc | 6.9M | -0.8x | --- |
Innovative Eyewear Inc | 7.2M | -0.7x | --- |
Company Information
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
Contact Information
- Headquarters
- 57 W 57th StNEW YORK, NY, United States 10019-2802
- Phone
- 150-922-2912
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
- Dewan Chowdhury
- Chief Operating Officer
- Arash Ghadar
- Director, Chief Business Officer
- Bashir Timol
- Independent Director
- Timothy Johnson
- Independent Director
- Thomas Moore
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.0M |
|---|---|
Revenue (TTM) | $77.1K |
Shares Outstanding | 28.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.41 |
EPS | $-0.49 |
Book Value | $-0.41 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 129.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -13,051.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
